A study of the drug RYZ101 for meningioma that grows or comes back
Original title: RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people to check safety and find the right dose.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing whether a radioactive drug called RYZ101 can help with meningioma.
Who this trial is for. This trial is for people with meningioma in the brain that is growing or has come back after getting better. It tests a radioactive drug called RYZ101, which sticks to a protein on some tumor cells and gives off radiation.
Where it stands. This trial has not reported results. It is looking at safety, side effects, the best dose, and how well RYZ101 works. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: Nothing here is proven yet. Someone whose tumor fits this picture could ask their care team about this trial and whether it makes sense for them.
What it doesn't mean: This does not mean RYZ101 works. A trial is a test, not a proven treatment. Being in one is not a promise that it will help. It is not a cure.
Source: ClinicalTrials.gov, August 13, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.